MHRA and UK Biobank are investigating whether pancreatitis risk on GLP-1s is genetic
Awaiting primary-source check
Following the January safety alert on acute pancreatitis, the MHRA and UK Biobank are working together to establish whether there is a genetic link between GLP-1 medicines and drug-induced acute pancreatitis, similar to the known link with the immunosuppressant thiopurine. Reporting alongside this noted 137 Yellow Card reports of acute and chronic pancreatitis for liraglutide between 2020 and 2026, one of which had a fatal outcome.
What this actually means
This is how a rare side effect gets properly understood rather than just counted.
If a genetic marker turns up, it could eventually mean a test that identifies the small number of people actually at risk, rather than a warning aimed at everyone. That is years away and may come to nothing.
In the meantime the practical advice is unchanged and worth repeating: severe, persistent stomach pain that may spread to your back, with nausea or vomiting, means seek medical attention rather than wait. One other thing the reporting highlights is that rapid weight loss itself can cause gallstones, which are a common cause of pancreatitis, so untangling cause from effect here is genuinely difficult.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.